Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial
Neeraj Agarwal, Arun Azad, Joan Carles, André P. Fay, Nobuaki Matsubara, Daniel Heinrich, Cezary Szczylik, Ugo De Giorgi, Jae Young Joung, Peter C.C. Fong, Éric Voog, Robert J. Jones, Neal D. Shore, Curtis Dunshee, Stefanie Zschäbitz, Jan Oldenburg, Xun Lin, Cynthia G. Healy, Nicola Di Santo, Fabian Zohren, Karim Fizazi
Topics & Concepts
EnzalutamideMedicineProstate cancerPlaceboInternal medicineClinical endpointOncologyPopulationDocetaxelAndrogen deprivation therapyAndrogen receptorCancerClinical trialPathologyAlternative medicineEnvironmental healthProstate Cancer Treatment and ResearchPARP inhibition in cancer therapyProstate Cancer Diagnosis and Treatment